Pirtobrutinib

Small molecule

Also known as LOXO-305, LY3527727

Approvedregulatory verdict

Evidence outlook

Approved: Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, Relapsed/Refractory Chronic Lymphocytic Leukemia

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also in development:Multiple Myeloma · Phase 1 · investigational in the US

Also approved (3)
CN
  • Jaypirca (pirtobrutinib) for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma, all lines of therapy regardless of prior covalent BTK inhibitor treatment
Product first approved 2026onclive.com
JP
  • Treatment of relapsed or refractory mantle cell lymphoma with resistance or intolerance to other BTK inhibitors
Product first approved 2024PMDA
EU
  • Jaypirca as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have been previously treated with a Bruton’s tyrosine kinase (BTK) inhibitor. Jaypirca as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (CLL).
Product first approved 2023EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (7)
Chronic Lymphocytic Leukemia
NCT07220187 · SWOG Cancer Research Network
2026-08-04 – 2036-10 · Richter Syndrome, Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma, Transformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma
What this study did
NCT05254743 · Loxo Oncology, Inc.
2022-07-22 – 2028-01 · Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma
What this study did
NCT04965493 · Loxo Oncology, Inc.
2021-09-20 – 2027-10 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
Mantle Cell Lymphoma
Relapsed/Refractory Chronic Lymphocytic Leukemia
NCT07516093 · Nurix Therapeutics, Inc.
2026-08-03 – 2033-08 · B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
Phase 2 (42)
Chronic Lymphocytic Leukemia
NCT07624799 · French Innovative Leukemia Organisation
2026-09-01 – 2033-09-01 · CLL (Chronic Lymphocytic Leukemia)
What this study did
NCT06967610 · M.D. Anderson Cancer Center
2025-07-15 – 2033-06-01 · Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia (SLL)
What this study did
NCT06043674 · Christine Ryan
2024-01-22 – 2033-01-15 · Chronic Lymphocytic Leukemia, Richter's Transformation
What this study did
NCT07860775 · Stichting Hemato-Oncologie voor Volwassenen Nederland
2026-09-15 – 2032-10-15 · CLL / SLL
What this study did
NCT06333262 · Inhye Ahn
2024-04-22 – 2032-07-01 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT06812715 · Peter MacCallum Cancer Centre, Australia
2025-05-05 – 2031-05 · Chronic Lymphocytic Leukemia
What this study did
NCT05677919 · Mayo Clinic
2023-01-31 – 2030-09-03 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT07685717 · Jennifer Woyach
2026-07-13 – 2027-12-31 · Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
What this study did
NCT06466122 · Kerry Rogers
2024-11-07 – 2026-12-31 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
Mantle Cell Lymphoma
NCT05833763 · Australasian Leukaemia and Lymphoma Group
2023-10-12 – 2037-04 · Mantle Cell Lymphoma, Mantle Cell Lymphoma Refractory
What this study did
NCT07285590 · Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
2025-09-30 – 2032-12 · Mantle Cell Lymphoma (MCL)
What this study did
NCT07944651 · Tianjin Medical University Cancer Institute and Hospital
2026-12-08 – 2030-12-08 · Mantle Cell Lymphoma (MCL), Relapsed/Refractory Mantle Cell Lymphoma (MCL)
What this study did
NCT07207785 · Fondazione Italiana Linfomi - ETS
2026-02-01 – 2030-02-01 · Mantle Cell Lymphoma
What this study did
NCT06553872 · H. Lee Moffitt Cancer Center and Research Institute
2024-08-23 – 2029-08 · Mantle Cell Lymphoma
What this study did
NCT07684950 · Henan Cancer Hospital
2026-06-30 – 2029-04-30 · Mantle Cell Lymphoma (MCL)
What this study did
NCT06522386 · M.D. Anderson Cancer Center
2025-01-30 – 2029-02-28 · Mantle Cell Lymphoma
What this study did
NCT06263491 · M.D. Anderson Cancer Center
2024-05-29 – 2028-11-01 · Mantle Cell Lymphoma
What this study did
NCT06252675 · University of California, San Francisco
2024-06-11 – 2028-07-31 · Mantle Cell Lymphoma
What this study did
NCT05529069 · M.D. Anderson Cancer Center
2023-01-25 – 2027-04-28 · Mantle Cell Lymphoma, Non Hodgkin Lymphoma, Hematologic Malignancy
What this study did
NCT04849416 · Eli Lilly and Company
2021-05-14 – 2025-12-29 · Leukemia, Lymphoid, Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Leukemia, Lymphocytic, Chronic, B-Cell
What this study did
Relapsed/Refractory Chronic Lymphocytic Leukemia
NCT06588478 · Loxo Oncology, Inc.
2025-01-03 – 2028-12 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
Other / comorbidity
NCT07548450 · University of Utah
2026-11 – 2035-11 · Waldenstrom Macroglobulinemia
What this study did
NCT05734495 · Dana-Farber Cancer Institute
2023-05-02 – 2033-01-25 · Waldenstrom Macroglobulinemia
What this study did
NCT06390956 · University of Utah
2025-02-20 – 2032-12 · Marginal Zone Lymphoma
What this study did
NCT07831395 · Institute of Hematology & Blood Diseases Hospital, China
2026-09-01 – 2031-12-31 · Richter Syndrome
What this study did
NCT06948786 · University of Washington
2025-11-17 – 2031-07-31 · Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma
What this study did
NCT07255963 · The First Affiliated Hospital of Soochow University
2025-11-30 – 2030-09-30 · DLBCL - Diffuse Large B Cell Lymphoma
What this study did
NCT07812493 · Pengpeng Xu
2026-09-01 – 2030-09-01 · Pirtobrutinib, Immunochemotherapy, DLBCL - Diffuse Large B Cell Lymphoma, CNS Involvement of Systemic Lymphoma
What this study did
NCT07416890 · Zhejiang Cancer Hospital
2026-02-10 – 2030-08-05 · Pirtobrutinib, Sintilimab, Central Nervous System Lymphoma
What this study did
NCT07744724 · Changzhou No.2 People's Hospital
2026-07-31 – 2030-07-31 · DLBCL - Diffuse Large B Cell Lymphoma, Pirtobrutinib
What this study did
NCT07917780 · German CLL Study Group
2026-06-18 – 2030-05-15 · Richter Transformation
What this study did
NCT07162181 · Eli Lilly and Company
2025-08-07 – 2030-05 · Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, B-cell Lymphoma
What this study did
NCT07744750 · Changzhou No.2 People's Hospital
2026-08-30 – 2029-08-31 · DLBCL - Diffuse Large B Cell Lymphoma, Richter Transformation, CLL / SLL, MZL
What this study did
NCT07774299 · Ruijin Hospital
2026-08-25 – 2029-08-25 · DLBCL
What this study did
NCT07744737 · Changzhou No.2 People's Hospital
2026-07-30 – 2029-04-30 · DLBCL - Diffuse Large B Cell Lymphoma, R-CHOP Chemotherapy, Pirtobrutinib
What this study did
NCT07622784 · Sun Yat-sen University
2026-06 – 2028-12 · Relapsed or Refractory B-cell Lymphoma
What this study did
NCT07231952 · Memorial Sloan Kettering Cancer Center
2025-11-11 – 2028-04-11 · Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma
What this study did
NCT06104683 · Loxo Oncology, Inc.
2024-05-01 – 2026-02-13 · Relapsing Multiple Sclerosis, Multiple Sclerosis
What this study did
Phase 1/2 (5)
Chronic Lymphocytic Leukemia
NCT07052695 · Inhye Ahn
2025-11-24 – 2032-12-31 · Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Lymphoma
What this study did
NCT05317936 · M.D. Anderson Cancer Center
2022-11-16 – 2025-10-06 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
Relapsed/Refractory Chronic Lymphocytic Leukemia
NCT04623541 · Genmab
2020-11-25 – 2028-02 · Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome, Treatment-naïve High Risk Chronic Lymphocytic Leukemia
What this study did
Other / comorbidity
NCT06721013 · Eli Lilly and Company
2025-07-30 – 2029-02 · Immune Thrombocytopenia (ITP)
What this study did
Phase 1 (17)
Chronic Lymphocytic Leukemia
NCT07428707 · National Heart, Lung, and Blood Institute (NHLBI)
2026-03-11 – 2030-03-01 · Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
What this study did
Mantle Cell Lymphoma
NCT05990465 · Medical College of Wisconsin
2025-02-06 – 2030-07 · Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Burkitt Lymphoma
What this study did
Multiple Myeloma
NCT05024045 · Eli Lilly and Company
2021-09-30 – 2026-03-02 · Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-cell Marginal Zone, Lymphoma, Non-Hodgkin, Multiple Myeloma, B-cell Lymphoma, Waldenstrom Macroglobulinemia, Lymphoma, Mantle-Cell
What this study did
Other / comorbidity
NCT05176314 · Loxo Oncology, Inc.
2022-01-11 – 2022-04-20 · Healthy
What this study did
NCT06190691 · Eli Lilly and Company
2020-12-18 – 2021-12-30 · Healthy, Hepatic Insufficiency
What this study did
NCT06258174 · Eli Lilly and Company
2021-09-28 – 2021-12-22 · Healthy
What this study did
NCT06194214 · Eli Lilly and Company
2021-03-11 – 2021-06-09 · Healthy
What this study did
NCT06190678 · Eli Lilly and Company
2021-02-01 – 2021-06-04 · Healthy, Renal Insufficiency
What this study did
NCT06215521 · Eli Lilly and Company
2020-12-15 – 2021-03-31 · Healthy
What this study did
NCT06180980 · Eli Lilly and Company
2021-01-04 – 2021-03-08 · Healthy
What this study did
NCT06165146 · Eli Lilly and Company
2020-11-10 – 2020-12-30 · Healthy
What this study did
NCT06181006 · Eli Lilly and Company
2020-08-14 – 2020-12-01 · Healthy
What this study did
NCT06180954 · Eli Lilly and Company
2020-09-23 – 2020-11-06 · Healthy
What this study did
NCT05134337 · Loxo Oncology, Inc.
2020-02-12 – 2020-10-30 · Healthy Volunteers
What this study did
NCT06180967 · Eli Lilly and Company
2020-09-03 – 2020-10-20 · Healthy
What this study did
NCT05134350 · Loxo Oncology, Inc.
2020-02-06 – 2020-03-23 · Healthy Volunteers
What this study did
Phase 4 (3)
Chronic Lymphocytic Leukemia
NCT06876662 · Eli Lilly and Company
2025-05-20 – 2032-12 · Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
What this study did
NCT06876649 · Eli Lilly and Company
2025-05-20 – 2032-12 · Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
What this study did
NCT07218341 · Eli Lilly and Company
2026-03-09 – 2032-12 · Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic
What this study did
Used as active comparator (3)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (3)
Mantle Cell Lymphoma
NCT07784101 · Beijing InnoCare Pharma Tech Co., Ltd.
2026-10 – 2033-12 · Relapsed or Refractory Mantle Cell Lymphoma (MCL)
What this study did
Relapsed/Refractory Chronic Lymphocytic Leukemia
NCT07342478 · Newave Pharmaceutical Inc
2026-04-23 – 2030-07-30 · CLL / SLL, CLL (Chronic Lymphocytic Leukemia), CLL, Refractory, CLL, Relapsed, SLL (Small Lymphocytic Lymphoma), SLL, CLL, CLL Progression
What this study did
NCT06973187 · BeOne Medicines
2025-09-04 – 2028-04-17 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 1 (1)
Chronic Lymphocytic Leukemia
NCT03666000 · Imugene Limited
2019-03-11 – 2027-06 · Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did

Competitive landscape

4 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Mantle Cell Lymphoma: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Pirtobrutinib: this drugApprovedSmall moleculeBTKnot yet gradedNo reviewed efficacy summary in this indication
AcalabrutinibApprovedSmall moleculeBTKWeak signal
NCT02213926: Overall Response Rate (ORR) of ACP-196 (Acalabrutinib) in Subjects With Previously Treated MCL. (From the date of the first dose until 30 days after the last dose of the study drug or start of a new anti-cancer treatment, whichever came first, assessed up to approximately 4 year and 10 months. 1 cycle =28 days): ACP-196 (Acalabrutinib) — CR: 59 Participants; PR: 42 Participants; SD: 10 Participants; PD: 10 Participants; NE: 3 Participants
BortezomibApprovedSmall moleculeProteasomenot yet gradedNo reviewed efficacy summary in this indication
LenalidomideApprovedSmall moleculeCereblon E3 ubiquitin-ligase, Thalidomide Analognot yet gradedNo reviewed efficacy summary in this indication
Rilzabrutinib
Approved(overall)
Small moleculeBTK
Reliable signal(overall)
No reviewed efficacy summary in this indication
Sonrotoclax (Beqalzi)ApprovedSmall moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
Zanubrutinib (Brukinsa)ApprovedSmall moleculeBTKWeak signal
NCT04002297: Primary endpoint, progression-free survival: zanubrutinib plus rituximab superior to bendamustine plus rituximab (BeOne topline, 2026-06-01).
NCT03206970: Overall response rate by independent review: 72/86 (83.7%, 95% CI 74.2 to 90.8), p<0.0001 against a null rate of 40% (single arm) (CT.gov posted results).
IbrutinibPhase 3Small moleculeBTKnot yet gradedNo reviewed efficacy summary in this indication
MesutoclaxPhase 3Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(49 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Pirtobrutinib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2026-12-31 · NCT06466122 · CT.gov ↗
What to watch
2027 (9)
February 2027 (1)
Phase 2Mantle Cell LymphomaActive not recruiting
Est. primary completion 2027-02-28 · NCT06522386 · CT.gov ↗
What to watch
April 2027 (1)
Phase 2Mantle Cell LymphomaRecruiting
Est. primary completion 2027-04-28 · NCT05529069 · CT.gov ↗
What to watch
July 2027 (2)
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2027-07-01 · NCT06333262 · CT.gov ↗
What to watch
Phase 2DLBCL - Diffuse Large B Cell Lymphoma, R-CHOP Chemotherapy, PirtobrutinibNot yet recruiting
Est. primary completion 2027-07-30 · NCT07744737 · CT.gov ↗
What to watch
August 2027 (1)
Phase 2DLBCL - Diffuse Large B Cell Lymphoma, Richter Transformation, CLL / SLL, MZLNot yet recruiting
Est. primary completion 2027-08-31 · NCT07744750 · CT.gov ↗
What to watch
October 2027 (1)
Phase 3Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2027-10 · NCT05254743 · CT.gov ↗
What to watch
November 2027 (1)
Phase 3Mantle Cell LymphomaActive not recruiting
Est. primary completion 2027-11 · NCT04662255 · CT.gov ↗
What to watch
December 2027 (2)
Phase 1/2Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2027-12 · NCT04623541 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2027-12-31 · NCT07685717 · CT.gov ↗
What to watch
2028 (20)
January 2028 (1)
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2028-01-15 · NCT06043674 · CT.gov ↗
What to watch
February 2028 (2)
Phase 1/2Immune Thrombocytopenia (ITP)Recruiting
Est. primary completion 2028-02 · NCT06721013 · CT.gov ↗
What to watch
Phase 2Mantle Cell LymphomaNot yet recruiting
Est. primary completion 2028-02-01 · NCT07207785 · CT.gov ↗
What to watch
April 2028 (2)
Phase 2Waldenstrom Macroglobulinemia, Lymphoplasmacytic LymphomaRecruiting
Est. primary completion 2028-04-11 · NCT07231952 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2028-04-25 · NCT05536349 · CT.gov ↗
What to watch
June 2028 (2)
Phase 2Relapsed or Refractory B-cell LymphomaNot yet recruiting
Est. primary completion 2028-06 · NCT07622784 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2028-06 · NCT06588478 · CT.gov ↗
What to watch
July 2028 (3)
Phase 1Mantle Cell LymphomaRecruiting
Est. primary completion 2028-07 · NCT05990465 · CT.gov ↗
What to watch
Phase 2DLBCL - Diffuse Large B Cell Lymphoma, PirtobrutinibNot yet recruiting
Est. primary completion 2028-07-31 · NCT07744724 · CT.gov ↗
What to watch
Phase 2Mantle Cell LymphomaRecruiting
Est. primary completion 2028-07-31 · NCT06252675 · CT.gov ↗
What to watch
August 2028 (2)
Phase 2Pirtobrutinib, Sintilimab, Central Nervous System LymphomaRecruiting
Est. primary completion 2028-08-05 · NCT07416890 · CT.gov ↗
What to watch
Phase 2DLBCLNot yet recruiting
Est. primary completion 2028-08-25 · NCT07774299 · CT.gov ↗
What to watch
September 2028 (3)
Phase 2Chronic Lymphocytic LeukemiaNot yet recruiting
Est. primary completion 2028-09-01 · NCT07624799 · CT.gov ↗
What to watch
Phase 2Pirtobrutinib, Immunochemotherapy, DLBCL - Diffuse Large B Cell Lymphoma, CNS Involvement of Systemic LymphomaNot yet recruiting
Est. primary completion 2028-09-01 · NCT07812493 · CT.gov ↗
What to watch
Phase 2DLBCL - Diffuse Large B Cell LymphomaRecruiting
Est. primary completion 2028-09-30 · NCT07255963 · CT.gov ↗
What to watch
October 2028 (1)
Phase 2Mantle Cell LymphomaNot yet recruiting
Est. primary completion 2028-10-30 · NCT07684950 · CT.gov ↗
What to watch
November 2028 (1)
Phase 2Mantle Cell LymphomaRecruiting
Est. primary completion 2028-11-01 · NCT06263491 · CT.gov ↗
What to watch
December 2028 (3)
Phase 2Mantle Cell LymphomaNot yet recruiting
Est. primary completion 2028-12-08 · NCT07944651 · CT.gov ↗
What to watch
Phase 1/2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2028-12-31 · NCT07052695 · CT.gov ↗
What to watch
Phase 2PCNSL, Primary Central Nervous System LymphomaRecruiting
Est. primary completion 2028-12-31 · NCT07350850 · CT.gov ↗
What to watch
2029 (4)
January 2029 (1)
Phase 2Waldenstrom MacroglobulinemiaActive not recruiting
Est. primary completion 2029-01-25 · NCT05734495 · CT.gov ↗
What to watch
May 2029 (1)
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2029-05 · NCT06812715 · CT.gov ↗
What to watch
August 2029 (1)
Phase 2Mantle Cell LymphomaRecruiting
Est. primary completion 2029-08 · NCT06553872 · CT.gov ↗
What to watch
October 2029 (1)
Phase 3Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2029-10 · NCT07516093 · CT.gov ↗
What to watch
2030 (8)
February 2030 (1)
Phase 1Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2030-02-01 · NCT07428707 · CT.gov ↗
What to watch
May 2030 (5)
Phase 2Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, B-cell LymphomaActive not recruiting
Est. primary completion 2030-05 · NCT07162181 · CT.gov ↗
What to watch
Phase 4Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2030-05 · NCT06876662 · CT.gov ↗
What to watch
Phase 4Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2030-05 · NCT06876649 · CT.gov ↗
What to watch
Phase 4Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2030-05 · NCT07218341 · CT.gov ↗
What to watch
Phase 2Richter TransformationRecruiting
Est. primary completion 2030-05-15 · NCT07917780 · CT.gov ↗
What to watch
October 2030 (1)
Phase 2Chronic Lymphocytic LeukemiaNot yet recruiting
Est. primary completion 2030-10-15 · NCT07860775 · CT.gov ↗
What to watch
December 2030 (1)
Phase 2Richter SyndromeNot yet recruiting
Est. primary completion 2030-12-31 · NCT07831395 · CT.gov ↗
What to watch
2031 (3)
June 2031 (1)
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2031-06-01 · NCT06967610 · CT.gov ↗
What to watch
July 2031 (1)
Phase 2Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma …Recruiting
Est. primary completion 2031-07-31 · NCT06948786 · CT.gov ↗
What to watch
December 2031 (1)
Phase 2Marginal Zone LymphomaRecruiting
Est. primary completion 2031-12 · NCT06390956 · CT.gov ↗
What to watch
2032 (2)
April 2032 (1)
Phase 2Mantle Cell LymphomaRecruiting
Est. primary completion 2032-04 · NCT05833763 · CT.gov ↗
What to watch
December 2032 (1)
Phase 2Mantle Cell LymphomaRecruiting
Est. primary completion 2032-12 · NCT07285590 · CT.gov ↗
What to watch
2034 (1)
November 2034 (1)
Phase 2Waldenstrom MacroglobulinemiaNot yet recruiting
Est. primary completion 2034-11 · NCT07548450 · CT.gov ↗
What to watch
2035 (1)
October 2035 (1)
Phase 3Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2035-10-01 · NCT07220187 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(7)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

2 October 2026ApprovalFDA approves Jaypirca for previously untreated CLL/SLL
US, FDA · Eli Lilly and Company · Source ↗
September 2026ApprovalNMPA approves Jaypirca for CLL/SLL across all lines of therapy in China
CN, NMPA · Innovent Biologics, Inc. · Source ↗
7 December 2025Topline resultBRUIN CLL-314 Phase 3 meets primary endpoint vs ibrutinib
3 December 2025ApprovalFDA approves expanded Jaypirca indication in R/R CLL/SLL
US, FDA · Source ↗
8 September 2025Topline resultBRUIN CLL-313 Phase 3 topline: pirtobrutinib improves PFS vs bendamustine plus rituximab
29 July 2025Topline resultPhase 3 BRUIN CLL-314 of pirtobrutinib versus ibrutinib met its primary endpoint
Eli Lilly · Source ↗
9 December 2024Topline resultBRUIN CLL-321 Phase 3 final analysis results